Investors & Media

Webcast ImageWebcast
GBT at the 2016 American Society of Hematology (ASH) Annual Meeting (Replay)
12/05/16 at 12:15 p.m. PT
GBT at the 2016 American Society of Hematology (ASH) Annual Meeting
Monday, December 5, 2016 12:15 p.m. PT  
Webcast PresentationHelp Help
Click here for webcast
Add to CalendarHelp Help
Add to Calendar Click here to add this event to your calendar
ASH 2016 Poster: Long-Term Dosing in Sickle Cell Disease Subjects with GBT440, a Novel HbS Polymerization Inhibitor
ASH 2016 Poster: The 9-Item Sickle Cell Disease Severity Measure (SCDSM): A Novel Measure of Daily SCD Symptom Severity Developed to Assess Benefit of GBT440, an Experimental HbS Polymerization Inhibitor
ASH 2016 Poster: Absorption, Metabolism, and Excretion of GBT440, a Novel Hemoglobin S (HbS) Polymerization Inhibitor for the Treatment of Sickle Cell Disease (SCD), in Healthy Male Subjects
Corporate Profile
Global Blood Therapeutics, Inc. (GBT), is a clinical-stage biopharmaceutical company dedicated to discovering, developing and commercializing novel therapeutics to treat grievous blood-based disorders with significant unmet need. We are developing our product candidate, GBT440, an oral, once-daily therapy that modulates hemoglobin affinity for oxygen. GBT440 potentially inhibits hemoglobin polymerization in sickle cell disease and potentially improves hypoxemia in idiopathic pulmonary fibrosis.... More >>
Stock Quote
GBT (Common Stock)
ExchangeNASDAQ GS (US Dollar)
Price$16.40
Change (%)0.00 (0.00%)
Volume0
Data as of 01/17/17 4:00 p.m. ET
Refresh quote
Corporate Presentation
Download Documentation 35th Annual J.P. Morgan Healthcare Conference Presentation
Get help downloading or viewing the above file types
Recent NewsMore >>
DateTitle 
01/03/17Global Blood Therapeutics to Present at the 35th Annual J.P. Morgan Healthcare Conference
SOUTH SAN FRANCISCO, Calif., Jan. 03, 2017 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ:GBT) today announced that it will present at the 35th Annual J.P. Morgan Healthcare Conference on Tuesday, January 10, 2017 at 3 p.m. Pacific Time at the Westin St. Francis Hotel in San Francisco.  The presentation and Q&A session will be webcast live and available for replay from GBT’s website at www.globalbloodtx.com in the Investors & Media section. About Global Blood The... 
Printer Friendly Version
12/16/16Global Blood Therapeutics Added to NASDAQ Biotechnology Index
SOUTH SAN FRANCISCO, Calif., Dec. 16, 2016 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ:GBT) today announced that it has been selected for addition to the NASDAQ Biotechnology Index® (Nasdaq:NBI). GBT’s addition to the NBI will become effective upon market open on Monday, December 19, 2016. The NASDAQ Biotechnology Index, which is re-ranked annually, is designed to track the performance of a set of NASDAQ-listed securities that are classified as either biotechnology or ... 
Printer Friendly Version
12/05/16Global Blood Therapeutics Announces New Details on its Novel Patient Reported Outcomes (PRO) Tool to be used in Phase 3 HOPE Study
-- PRO designed to establish clinical benefit – -- First time a PRO to be used as a secondary clinical endpoint in a SCD registrational study -- --Company to Host Webcast Today at 12:15 p.m. PT to Discuss ASH Data Presentations — SOUTH SAN FRANCISCO, Calif., Dec. 05, 2016 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ:GBT) today announced that the methodology used to develop the Patient Reported Outcome (PRO) tool that will be used as a secondary clinical endpoint in th... 
Printer Friendly Version
12/04/16Global Blood Therapeutics Announces New Long-Term Clinical Data from Ongoing Phase 1/2 Trial of GBT440 in Sickle Cell Disease at ASH
--Results Showed GBT440 Treatment Led to Rapid, Significant, Profound and Durable Reduction in Hemolysis and Sickled Cells in All Patients Treated for Up to Six Months-- --Company to Host Webcast Tomorrow at 12:15 p.m. PT to Discuss Data-- SOUTH SAN FRANCISCO, Calif., Dec. 04, 2016 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ:GBT) today announced the presentation of results from its ongoing Phase 1/2 GBT440-001 study that further support the safety and efficacy profile o... 
Printer Friendly Version
Upcoming EventsMore >>
There are currently no events scheduled.
Receive E-mail Alerts
Sign up to receive e-mail alerts whenever Global Blood Therapeutics Inc posts new information to the site. Just enter your e-mail address and click Submit.
 
Data provided by Nasdaq. Minimum 15 minutes delayed.